When planning a first-in-human MedTech clinical trial, many companies instinctively look to the United States or Europe. Yet Australia is increasingly becoming part of that conversation much earlier in the planning process.
The reason is simple. Australia offers a unique combination of regulatory efficiency, experienced investigators, financial incentives, and clinical expertise that can make it an attractive destination for early stage device development.
Every development program is different, and Australia is not the right fit for every study. But for many sponsors, it deserves a closer look.
A pathway designed for early clinical research
Australia’s Clinical Trial Notification (CTN) scheme offers an efficient framework for initiating clinical studies. Scientific and ethical review is conducted through Human Research Ethics Committees (HRECs), while the Therapeutic Goods Administration (TGA) oversees the broader regulatory environment.
While timelines vary by study, sponsors often find Australia’s approach well suited to the needs of early stage innovation.
Clinical data that supports global development
An Australian FIH study is not simply a local exercise.
When designed and conducted according to Good Clinical Practice requirements, data generated in Australia can contribute to broader global development strategies, including future regulatory submissions.
For many sponsors, that means an Australian study can provide important early evidence while helping advance worldwide development goals.
Financial incentives can stretch development budgets
Australia’s R&D Tax Incentive remains one of the country’s most compelling advantages for emerging MedTech companies.
Eligible organizations may be able to claim a significant portion of qualifying R&D expenditures, helping offset clinical development costs and extend valuable runway during a capital intensive stage of growth.
For startups and growth stage companies, those savings can create flexibility at a stage when every development dollar matters.
Experienced investigators and research infrastructure
Australia has a mature clinical research ecosystem with experienced investigators, specialized clinical sites, and established research networks.
Many U.S. and European sponsors find the operating environment familiar and well equipped to support complex medical device studies, including first-in-human programs.
Australia’s long history of conducting high-quality clinical research continues to attract companies bringing new technologies into human studies, supported on the ground by Avania’s Australia-based team.
Strong recruitment opportunities
Patient recruitment can significantly impact development timelines.
Australia’s established clinical networks, concentrated healthcare systems, and experienced research sites can help support efficient enrollment for many device studies. In addition, seasonal differences from the Northern Hemisphere may provide opportunities to maintain study momentum throughout the year.
As with every trial, recruitment success depends on the indication, patient population, and study design, but many sponsors find Australia compares favorably with larger markets.
Success depends on more than a regulatory pathway
The success of a first-in-human study ultimately comes down to execution.
Avania’s Australia-based team specializes in supporting MedTech innovators through the unique requirements of first-in-human clinical research. From study planning and start-up through enrollment, procedures, monitoring, and closeout, our team works alongside sponsors, investigators, and sites, drawing on Avania’s clinical development capabilities to help navigate challenges before they become obstacles.
Our Field Clinical Specialists are in hospitals and procedure rooms supporting cases before, during, and after they occur. Their experience helps investigators and site teams address issues early while maintaining focus on patient safety and study quality.
First-in-human studies are about more than data.
They involve patients who are receiving a technology for the first time and investigators who are willing to lead the way with a new innovation. Both deserve a team that has been there before.
Start the conversation
Choosing where to conduct a first-in-human study is one of the most important decisions a MedTech company will make.
Australia may not be the right answer for every program, but it is often worth considering far earlier than many sponsors realize.
In future articles, we will take a deeper look at the specific advantages of conducting first-in-human studies in Australia, including regulatory pathways, tax incentives, investigator networks, recruitment strategies, and clinical execution.
Considering a first-in-human MedTech study? Tell us about your project and our Australia team will help you assess whether it is the right fit for your development strategy. Prefer to talk first?
Connect with our Australia team directly.
Frequently asked questions
What is Australia’s CTN scheme?
The Clinical Trial Notification (CTN) scheme is Australia’s regulatory pathway for initiating clinical studies. Human Research Ethics Committees conduct scientific and ethical review, while the Therapeutic Goods Administration oversees the broader regulatory environment.
Can data from an Australian first-in-human study support a future FDA or CE submission?
When a study is designed and conducted according to Good Clinical Practice requirements, data generated in Australia can contribute to a broader global development strategy. Sponsors should confirm submission strategy with their regulatory team for their specific program.
What is Australia’s R&D Tax Incentive?
It is a program that allows eligible companies to claim back a portion of qualifying research and development expenditure, which can help offset the cost of early stage clinical development. Eligibility and reclaim rates should be confirmed with a qualified advisor for each program.
How does Australia compare to the US or Europe for a first-in-human study?
Australia offers regulatory efficiency, an established investigator network, and financial incentives that can complement a broader multi-region development strategy. It is not a fit for every program, and the right choice depends on the device, indication, and overall regulatory plan.
Who runs first-in-human studies for Avania in Australia?
Avania’s Australia-based team, including on the ground Field Clinical Specialists, supports sponsors through study planning, start-up, enrollment, procedures, monitoring, and closeout.